Lineage Cell Therapeutics
LCTX
102 hedge funds and large institutions have $142M invested in Lineage Cell Therapeutics in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 28 increasing their positions, 18 reducing their positions, and 10 closing their positions.
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
56% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 18
46% more capital invested
Capital invested by funds: $96.9M → $142M (+$44.9M)
15% more funds holding
Funds holding: 89 → 102 (+13)
0.6% more ownership
Funds ownership: 36.72% → 37.32% (+0.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
32% less call options, than puts
Call options by funds: $400K | Put options by funds: $588K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$2.7M |
| 2 |
Millennium Management
New York
|
+$2.57M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.07M |
| 4 |
BlackRock
New York
|
+$2.07M |
| 5 |
Two Sigma Investments
New York
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.56M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$1.14M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$292K |
| 4 |
Capstone Investment Advisors
New York
|
-$255K |
| 5 |
LWM
Laidlaw Wealth Management
New York City,
New York
|
-$132K |
LCTX Hedge Fund Activity: Q1 2021 in Review
102 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2021, worth a combined $142M — up 46% from $96.9M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new LCTX positions and 10 closed out — a net gain of 15 holders — while 28 added to existing stakes and 18 trimmed.
The largest buyer was Two Sigma Advisers, adding an estimated $2.7M. The largest seller was Vanguard Group, cutting an estimated $1.56M.
- 102 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2021, up from 89 in Q4 2020.
- Funds reported $142M of Lineage Cell Therapeutics stock for Q1 2021, up 46% quarter-over-quarter.
- 25 funds opened new Lineage Cell Therapeutics positions in Q1 2021 and 10 closed out, a net change of +15 holders.
- The largest Lineage Cell Therapeutics buyer in Q1 2021 was Two Sigma Advisers, an estimated $2.7M added.
- The largest Lineage Cell Therapeutics seller in Q1 2021 was Vanguard Group, an estimated $1.56M sold.
Based on aggregated 13F filings for Q1 2021.